Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice

Vaccine

Volumn 34, Issue 10, 2016, Pages 1252-1258

  Rappazzo, C Garrett ^a   Watkins, Hannah C ^a   Guarino, Cassandra M ^a   Chau, Annie ^b   Lopez, Jody L ^c   DeLisa, Matthew P ^a   Leifer, Cynthia A ^c   Whittaker, Gary R ^c   Putnam, David ^a  

^a School of Operations Research and Industrial Engineering   (United States)

^b Department of Biological and Environmental Engineering   (United States)

^c Department of Obstetrics Gynecology   (United States)

Author keywords

M2e subunit vaccines; Outer membrane vesicles; TLR agonists; Universal influenza vaccine

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INFLUENZA VACCINE; PROTEIN M2; RECOMBINANT M2E OUTER MEMBRANE VESICLE VACCINE; RECOMBINANT VACCINE; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; NANOPARTICLE; TOLL LIKE RECEPTOR; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; FEMALE; HETEROLOGOUS IMMUNITY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTECTION; SURVIVAL; AGONISTS; ANIMAL; BLOOD; ESCHERICHIA COLI; EXOSOME; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INNATE IMMUNITY; METABOLISM; ORTHOMYXOVIRIDAE INFECTIONS;

ANIMALS; ANTIBODIES, VIRAL; ESCHERICHIA COLI; EXTRACELLULAR VESICLES; FEMALE; IMMUNITY, INNATE; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE, INBRED BALB C; NANOPARTICLES; ORTHOMYXOVIRIDAE INFECTIONS; TOLL-LIKE RECEPTORS; VACCINES, SYNTHETIC; VIRAL MATRIX PROTEINS;

EID: 84958781249     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.01.028     Document Type: Article

References (40)

1. World Health Organization. Seasonal Influenza Fact Sheet 2014. http://www.who.int/mediacentre/factsheets/fs211/en/.
2. Centers for Disease Control and Prevention (U.S.). CDC Resources for Pandemic Flu 2014. http://www.cdc.gov/flu/pandemic-resources/index.htm.
3. Treanor J.J. Prospects for broadly protective influenza vaccines. Vaccine 2015, 1:7. 10.1016/j.vaccine.2015.08.053.
4. Schotsaert M., García-Sastre A. Influenza vaccines: a moving interdisciplinary field. Viruses 2014, 6:3809-3826. 10.3390/v6103809.
5. Krammer F., Palese P. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov 2015, 14:167-182. 10.1038/nrd4529.
6. Lamb R.A., Zebedee S.L., Richardson C.D. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 1985, 40:627-633. 10.1016/0168-1702(85)90260-6.
7. Lamb R.A., Choppin P.W. Identification of a second protein (M2) encoded by RNA segment 7 of influenza virus. Virology 1981, 112:729-737. 10.1016/0042-6822(81)90317-2.
8. Leser G.P., Lamb R.A. Influenza virus assembly and budding in raft-derived microdomains: a quantitative analysis of the surface distribution of HA, NA and M2 proteins. Virology 2005, 342:215-227. 10.1016/j.virol.2005.09.049.
9. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172:5598-5605. 10.4049/jimmunol.172.9.5598.
10. El Bakkouri K., Descamps F., De Filette M., Smet A., Festjens E., Birkett A., et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011, 186:1022-1031. 10.1016/j.ymed.2011.08.035.
11. Guilliams M., Bruhns P., Saeys Y., Hammad H., Lambrecht B.N. The function of Fcγ receptors in dendritic cells and macrophages. Nat Rev Immunol 2014, 14:94-108. 10.1038/nri3582.
12. Schmitz N., Beerli R.R., Bauer M., Jegerlehner A., Dietmeier K., Maudrich M., et al. Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol 2012, 42:863-869. 10.1002/eji.201041225.
13. De Filette M., Ramne A., Birkett A., Lycke N., Löwenadler B., Min Jou W., et al. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 2006, 24:544-551. 10.1016/j.vaccine.2005.08.061.
14. Schotsaert M., Ysenbaert T., Neyt K., Ibañez L.I., Bogaert P., Schepens B., et al. Natural and long-lasting cellular immune responses against influenza in the M2e-immune host. Mucosal Immunol 2012, 6:276-287. 10.1038/mi.2012.69.
15. Tsybalova L.M., Stepanova L.A., Kuprianov V., Blokhina E.A., Potapchuk M., Korotkov A., et al. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: broad protective efficacy of particles carrying four copies of M2e. Vaccine 2015, 33:3398-3406. 10.1016/j.vaccine.2015.04.073.
16. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5:1157-1163. 10.1038/13484.
17. Kim O.Y., Hong B.S., Park K.S., Yoon Y.J., Choi S.J., Lee W.H., et al. Immunization with Escherichia coli outer membrane vesicles protects bacteria-induced lethality via Th1 and Th17 cell responses. J Immunol 2013, 190:4092-4102. 10.4049/jimmunol.1200742.
18. Rosenthal J.A., Huang C., Doody A.M., Leung T., Mineta K., Feng D.D., et al. Mechanistic insight into the Th1-biased immune response to recombinant subunit vaccines delivered by probiotic bacteria-derived outer membrane vesicles. PLOS ONE 2014, 9:e112802. 10.1371/journal.pone.0112802.
19. Kim J.Y., Doody A.M., Chen D.J., Cremona G.H., Shuler M.L., Putnam D., et al. Engineered bacterial outer membrane vesicles with enhanced functionality. J Mol Biol 2008, 380:51-66. 10.1016/j.jmb.2008.03.076.
20. Chen D.J., Osterrieder N., Metzger S.M., Buckles E., Doody A.M., DeLisa M.P., et al. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc Natl Acad Sci U S A 2010, 107:3099-3104. 10.1073/pnas.0805532107.
21. Hamilton B.S., Chung C., Cyphers S.Y., Rinaldi V.D., Marcano V.C., Whittaker G.R. Inhibition of influenza virus infection and hemagglutinin cleavage by the protease inhibitor HAI-2. Biochem Biophys Res Commun 2015, 450:1070-1075. 10.1016/j.bbrc.2014.06.109.Inhibition.
22. De Filette M., Jou W.M., Birkett A., Lyons K., Schultz B., Tonkyro A., et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 2005, 337:149-161. 10.1016/j.virol.2005.04.004.
23. Liu W., Zou P., Ding J., Lu Y., Chen Y.H. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect 2005, 7:171-177. 10.1016/j.micinf.2004.10.006.
24. Kim M.C., Lee J.S., Kwon Y.M., Eunju O., Lee Y.J., Choi J.G., et al. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection. Antivir Res 2013, 99:328-335. 10.1016/j.antiviral.2013.06.010.
25. Kim M.C., Song J.M., Eunju O., Kwon Y.M., Lee Y.J., Compans R.W., et al. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther 2013, 21:485-492. 10.1038/mt.2012.246.
26. Watanabe H., Numata K., Ito T., Takagi K., Matsukawa A. Innate immune response in Th1- and Th2-dominant mouse strains. Shock 2004, 22:460-466. 10.1097/01.shk.0000142249.08135.e9.
27. Lee Y.N., Kim M.C., Lee Y.T., Hwang H.S., Cho M.K., Lee J.S., et al. AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection. Vaccine 2014, 32:4578-4585. 10.1016/j.vaccine.2014.06.040.
28. Ibañez L.I., Roose K., De Filette M., Schotsaert M., De Sloovere J., Roels S., et al. M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A. PLOS ONE 2013, 8. 10.1371/journal.pone.0059081.
29. Kim M.C., Lee Y.J.Y.N., Ko E.J., Lee J.S., Kwon Y.M., Hwang H.S., et al. Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection. Mol Ther 2014, 22:1364-1374. 10.1038/mt.2014.33.
30. Fiers W., De Filette M., Birkett A., Neirynck S., Min Jou W. A universal human influenza A vaccine. Virus Res 2004, 103:173-176. 10.1016/j.virusres.2004.02.030.
31. Maisonneuve C., Bertholet S., Philpott D.J., De Gregorio E. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci U S A 2014, 111:1-6. 10.1073/pnas.1400478111.
32. Kuehn M.J., Kesty N.C. Bacterial outer membrane vesicles and the host-pathogen interaction. Genes Dev 2005, 264:5-55. 10.1101/gad.1299905.negative.
33. Adler-Moore J., Munoz M., Kim H., Romero J., Tumpey T., Zeng H., et al. Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine. Vaccine 2011, 29:4460-4468. 10.1016/j.vaccine.2011.04.040.
34. Ernst W.A., Kim H.J., Tumpey T.M., Jansen A.D.A., Tai W., Cramer D.V., et al. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 2006, 24:5158-5168. 10.1016/j.vaccine.2006.04.008.
35. Deng L., Cho K., Fiers W., Saelens X. M2e-based universal influenza A vaccines. Vaccine 2015, 3:105-136. 10.3390/vaccines3010105.
36. Wu F., Yuan X.Y., Li J., Chen Y.H. The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine. Vaccine 2009, 27:4320-4324. 10.1016/j.vaccine.2009.04.075.
37. Ravin N.V., Blokhina E.A., Kuprianov V.V., Stepanova L.A., Shaldjan A.A., Kovaleva A., et al. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: insertion of multiple copies of M2e increases immunogenicity and protective efficacy. Vaccine 2015, 33:3392-3397. 10.1016/j.vaccine.2015.04.066.
38. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., et al. Preclinical study of influenza virus a M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22:2993-3003. 10.1016/j.vaccine.2004.02.021.
39. Kaparakis-Liaskos M., Ferrero R.L. Immune modulation by bacterial outer membrane vesicles. Nat Rev Immunol 2015, 15:375-387. 10.1038/nri3837.
40. Duthie M.S., Windish H.P., Fox C.B., Reed S.G. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011, 239:178-196. 10.1111/j.1600-065X.2010.00978.x.